New Publication from Exosome Diagnostics Demonstrates Proof-of-Concept for Monitoring Astronaut Health in Space
prnewswire.com
news
2022-10-18 11:00:00

Study indicates that noninvasive exosome-based liquid biopsy would be feasible for monitoring health and disease in people traveling in space
MINNEAPOLIS, Oct. 18, 2022 /PRNewswire/ --Â Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported results from a proof-of-concept study for a novel exosome-based platform that could monitor key biological changes in astronauts in space. The peer-reviewed publication was issued in npj Microgravity, a Nature publication.
